drugset / Trial / NCT00003357
Vaccine Therapy Plus QS21 in Treating Women With Breast Cancer Who Have No Evidence of Disease
Phase 1
Completed
9 enrolled
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI) · collab
Treatment
Summary
RATIONALE: Vaccines made from GM2-KLH and given with QS21 may make the body build an immune response to and kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of GM2-KLH vaccine plus QS21 in treating patients with breast cancer who have no evidence of disease.
Timeline
- Start
- 1998-01
- Primary completion
- 2001-11
- Completion
- 2001-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GM2-KLH | Vaccine | — | Subcutaneous |
| Background | QS-21 | Other / unclassified | — | Subcutaneous |